Alembic Pharmaceuticals Gains USFDA Nod for Cancer Fighting Injection

Alembic Pharmaceuticals has secured final USFDA approval for its generic version of Doxorubicin Hydrochloride Liposome, a cancer treatment. This approval allows the usage of single-dose vials for ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma. The product has an estimated USD 29 million market size.

Devdiscourse News Desk | New Delhi | Updated: 30-06-2025 12:17 IST | Created: 30-06-2025 12:17 IST

Alembic Pharmaceuticals Gains USFDA Nod for Cancer Fighting Injection — This image is AI-generated and does not depict any real-life event or location. It is a fictional representation created for illustrative purposes only.

Country:
India

Alembic Pharmaceuticals recently announced receiving the USFDA's final approval for their generic version of Doxorubicin Hydrochloride Liposome injection. This cancer treatment is designed to combat ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma.

The USFDA's approval covers single-dose vials of strengths 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL), which are therapeutically equivalent to Doxil Liposome Injection, manufactured by Baxter Healthcare Corporation.

According to data from IQVIA cited by Alembic, the expected market size for this injectable drug is approximately USD 29 million for the year ending March 2025.

(With inputs from agencies.)